An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced the release of its second-quarter 2023 financial results on August 14th, followed by a live conference call on August 15th to discuss business updates. The company is currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke.
Positive
None.
Negative
None.
MINNEAPOLIS--(BUSINESS WIRE)--
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Monday, August 14th. DiaMedica will host a live conference call on Tuesday, August 15th at 7:00 AM Central Time to provide a business update and discuss financial results.
Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until August 22, 2023, by dialing (800) 645-7964 (US Toll Free) and entering the replay passcode: 2125#.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active and clinically studied recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke and other vascular diseases. For more information visit our website at www.diamedica.com.
When will DiaMedica Therapeutics release its second-quarter 2023 financial results?
DiaMedica Therapeutics will release its second-quarter 2023 financial results after the markets close on Monday, August 14th.
What is DiaMedica's focus in terms of drug development?
DiaMedica is currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke.
When is the live conference call to discuss business updates and financial results?
The live conference call to discuss business updates and financial results will be held on Tuesday, August 15th at 7:00 AM Central Time.
How can interested parties access the conference call?
Interested parties can access the conference call by dialing in or listening to the simultaneous webcast. Web access and dial-in details are available on the company's website.
diamedica therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with the focus on neurological and kidney diseases. for more information please visit www.diamedica.com.
